Founded 2008
Public 2016 (NASDAQ: EIGR)
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development and commercialization of a broad range of therapeutics, with special expertise in Orphan Designation drugs.
Contact
(P) 650-272-6138
(F) 650-618-1621
www.eigerbio.com
Info@eigerbio.com
Public 2016 (NASDAQ: EIGR)
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development and commercialization of a broad range of therapeutics, with special expertise in Orphan Designation drugs.
Contact
(P) 650-272-6138
(F) 650-618-1621
www.eigerbio.com
Info@eigerbio.com
Location: United States, California, Palo Alto
Employees: 11-50
Phone: (650) 272-6138
Total raised: $7.1M
Founded date: 2008
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.02.2009 | - | $7.1M | - |
Mentions in press and media 27
| Date | Title | Description |
| 06.01.2022 | Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones | PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and ... |
| 22.12.2021 | Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection | PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and... |
| 15.12.2021 | Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients | PALO ALTO, Calif., Dec. 15, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and... |
| 01.12.2021 | Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting | PALO ALTO, Calif., Dec. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and ... |
| 01.11.2021 | Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV | PALO ALTO, Calif., Nov. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rar... |
| 20.09.2021 | Eiger BioPharmaceuticals : Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients | PALO ALTO, Calif., Sept. 20, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-... |
| 05.08.2021 | Eiger BioPharmaceuticals : Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism | PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-ra... |
| 05.08.2021 | Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism | |
| 06.07.2021 | Eiger BioPharmaceuticals : Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients | PALO ALTO, Calif., July 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rar... |
| 06.07.2021 | Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients |
Show more